LEADER 03191nam  2200709 a 450 
001 9910829111903321
005 20200520144314.0
010   $a9786612348259
010   $a9781282348257
010   $a1282348256
010   $a9780470518137
010   $a0470518138
010   $a9780470518144
010   $a0470518146
035   $a(CKB)1000000000377297
035   $a(EBL)470145
035   $a(OCoLC)609848709
035   $a(SSID)ssj0000302308
035   $a(PQKBManifestationID)11212294
035   $a(PQKBTitleCode)TC0000302308
035   $a(PQKBWorkID)10267089
035   $a(PQKB)10325685
035   $a(MiAaPQ)EBC470145
035   $a(Au-PeEL)EBL470145
035   $a(CaPaEBR)ebr10297756
035   $a(CaONFJC)MIL234825
035   $a(OCoLC)144568198
035   $a(FINmELB)ELB178416
035   $a(Perlego)2770913
035   $a(EXLCZ)991000000000377297
100   $a20070610d2007      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aManagement strategies in antithrombotic therapy /$fby Arman Askari and Adrian W. Messerli
205   $a1st ed.
210   $aChichester ;$aHoboken, N.J. $cJohn Wiley and Sons$dc2007
215   $a1 online resource (372 p.)
300   $aDescription based upon print version of record.
311 08$a9780470319383 
311 08$a0470319380 
320   $aIncludes bibliographical references and index.
327   $aThrombosis and antithrombotics in vascular disease -- Aspirin -- Thienopyridines, ticlopidine, and clopidogrel -- Platelet glycoprotein IIb/IIIa inhibitors -- Unfractionated heparin -- Low-molecular-weight heparins -- Direct thrombin inhibitors -- Fibrinolytic agents -- Acute ST-segment elevation myocardial infarction -- Acute coronary syndromes / non-ST-segment elevation myocardial infarction -- Anticoagulation strategies for patients undergoing percutaneous coronary intervention -- Venous thromboembolic disease -- Heparin-induced thrombocytopenia.
330   $aIntravascular thrombus formation remains one of the most significant problems in cardiovascular medicine. It underlies the clinical presentation of acute coronary syndromes, including unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction. More and more individuals are stricken with an acute MI and undergo a percutaneous coronary intervention (PCI). Several reasons apply, including an increasingly aged population, the growing burden of chronic risk factors such as diabetes, obesity, sedentary behaviour, and improvements in e
606   $aThrombolytic therapy
606   $aThrombosis$xTreatment
606   $aFibrinolytic agents
615  0$aThrombolytic therapy.
615  0$aThrombosis$xTreatment.
615  0$aFibrinolytic agents.
676   $a616.1/42
700   $aAskari$b Arman T$01670666
701   $aMesserli$b Adrian W$01670667
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910829111903321
996   $aManagement strategies in antithrombotic therapy$94032673
997   $aUNINA